Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Triple Negative Breast Cancer
Interventions: DRUG: TPC|DRUG: Bicalutamide 150 mg
Sponsor: Sun Yat-sen University